DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus (MRSA) Osteomyelitis (VOTSMO)

Information source: University of Washington
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteomyelitis; Methicillin-resistant Staphylococcus Aureus

Intervention: trimethoprim-sulfamethoxazole (Drug); vancomycin (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: University of Washington

Official(s) and/or principal investigator(s):
Timothy H. Dellitt, MD, Principal Investigator, Affiliation: UW
Jeanne Chan, PharmD, MPH, Principal Investigator, Affiliation: UW
Matthew Golden, MD, MPH, Principal Investigator, Affiliation: UW
M. Bradford Henley, MD, Principal Investigator, Affiliation: UW
Jeanne M Marrazzo, MD, MPH, Principal Investigator, Affiliation: UW
Lisa Taitsman, MD, Principal Investigator, Affiliation: UW
Thomas R Hawn, MD, PhD, Principal Investigator, Affiliation: UW
Robert D Harrington, MD, Principal Investigator, Affiliation: UW
Christian Ramers, MD, Principal Investigator, Affiliation: University of Washington


The primary question of this study is to understand if trimethoprim-sulfamethoxazole (TMP-SMX) is as effective as vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.

Clinical Details

Official title: A Prospective, Randomized Trial Comparing Vancomycin With Trimethoprim/Sulfamethoxazole for the Treatment of MRSA Osteomyelitis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Clinical cure at 12 months

Detailed description: Treatment of osteomyelitis is hampered by a paucity of evidence from prospective clinical trials with randomized treatment arms. Furthermore, previous randomized or observational trials have enrolled small numbers of subjects and thus often had non-definitive findings. One of the most common causes of osteomyelitis is Staphylococcus aureus. Over the past 10 years, rates of methicillin-resistant S. aureus (MRSA) have risen dramatically. Vancomycin is currently the treatment of choice for treating MRSA. While vancomycin is effective, it is only available in intravenous formulation and has renal and bone marrow toxicities. There is a critical need for effective, oral, cheap drugs for the treatment of MRSA. Trimethoprim-sulfamethoxazole (TMP-SMX) is a drug with several advantageous properties for the treatment of MRSA osteomyelitis. To address this question regarding optimal treatment of MRSA osteomyelitis, we designed a prospective, randomized trial comparing TMP-SMX with vancomycin for the treatment of MRSA osteomyelitis.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Culture-proven MRSA, obtained in operating room or sterile biopsy procedure from bone site. The infection and sampling site can either be within bone or a deep soft-tissue site that is contiguous with bone; OR radiographic abnormality consistent with osteomyelitis in conjunction with a positive blood culture for MRSA. 2. Surgical debridement of infection site, as needed. 3. Subject is capable of providing written informed consent. 4. Subject is at least 18 years of age. 5. Subject capable of receiving outpatient parenteral therapy for 12 weeks. Exclusion Criteria: 1. Hypersensitivity to TMP-SMX or vancomycin. 2. S. aureus resistant to TMP-SMX or vancomycin. 3. Osteomyelitis that develops directly from a chronic, open wound. 4. Polymicrobial culture(the only exception is if coagulase-negative staphylococcus is present in the culture and the clinical assessment is that it is a contaminant). 5. Subject has a positive pregnancy test at study enrollment. 6. Convicted felon currently in prison. 7. Baseline renal or hepatic insufficiency that would preclude administration of study drugs. 8. Active injection drug use without safe conditions to administer intravenous antibiotics for 3 months. 9. Anticipated use of antibiotics for greater than 14 days for an infection other than osteomyelitis.

Locations and Contacts

University of Washington, Seattle, Washington 98104, United States
Additional Information

Starting date: May 2006
Last updated: July 27, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017